Living Cell Technologies Limited (LVCLY) Research

Living Cell Technologies Limited (LCT) is a biotechnology company dedicated to the innovation, development, and market introduction of regenerative medical therapies. These treatments leverage naturally occurring cells with the aim of restoring physiological functions, particularly within New Zealand. A primary focus for LCT is NTCELL, a novel alginate-coated capsule currently progressing through Phase IIb clinical trials for its application in treating Parkinson's disease. The company was founded in 1987 and operates from its base in Sydney, Australia.

Market snapshot

Symbol
LVCLY
Price
$0.03
Day change
+24.39%
Market cap
$24.5M
P/E ratio
-11.55x
52-week range
0.02-0.08
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Antibe Therapeutics Inc. (ATBPF)
  • Avecho Biotechnology Limited (AVEFF)
  • Bionomics Limited (BNOEF)
  • Ceapro Inc. (CRPOF)
  • Eiger BioPharmaceuticals, Inc. (EIGRQ)
  • LexaGene Holdings Inc. (LXXGF)
  • Noxopharm Limited (NOXOF)
  • Poxel S.A. (PXXLF)

Open Living Cell Technologies Limited (LVCLY) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.